Xi‐Fei Jiang

1.1k total citations
24 papers, 534 citations indexed

About

Xi‐Fei Jiang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Xi‐Fei Jiang has authored 24 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 10 papers in Surgery. Recurrent topics in Xi‐Fei Jiang's work include Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers), Gallbladder and Bile Duct Disorders (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Xi‐Fei Jiang is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers), Gallbladder and Bile Duct Disorders (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Xi‐Fei Jiang collaborates with scholars based in China, Ethiopia and India. Xi‐Fei Jiang's co-authors include Jia Fan, Meng‐Xin Tian, Zhen‐Bin Ding, Jian Zhou, Yuan‐Fei Peng, Ying‐Hong Shi, Wei‐Ren Liu, Pei‐Yun Zhou, Lei Jin and Wei‐Feng Qu and has published in prestigious journals such as Oncogene, Nanoscale and British Journal of Cancer.

In The Last Decade

Xi‐Fei Jiang

23 papers receiving 529 citations

Peers

Xi‐Fei Jiang
Chao‐Nan Qian China
Norifumi Hattori Japan
Thomas Armstrong United Kingdom
Laura July Canada
Chunyan Luan United States
Junyan Xu China
Bettina Schwarz Germany
Augusto J. Bastidas United States
Jan Sun United States
Chao‐Nan Qian China
Xi‐Fei Jiang
Citations per year, relative to Xi‐Fei Jiang Xi‐Fei Jiang (= 1×) peers Chao‐Nan Qian

Countries citing papers authored by Xi‐Fei Jiang

Since Specialization
Citations

This map shows the geographic impact of Xi‐Fei Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xi‐Fei Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xi‐Fei Jiang more than expected).

Fields of papers citing papers by Xi‐Fei Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xi‐Fei Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xi‐Fei Jiang. The network helps show where Xi‐Fei Jiang may publish in the future.

Co-authorship network of co-authors of Xi‐Fei Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Xi‐Fei Jiang. A scholar is included among the top collaborators of Xi‐Fei Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xi‐Fei Jiang. Xi‐Fei Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dong, Jihong, Yong Zhang, Sushan Luo, et al.. (2025). Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial. Journal of Thoracic Oncology. 20(8). 1120–1130.
2.
Wang, Han, Fangming Liu, Xiaoling Wu, et al.. (2024). Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogramming. Experimental Cell Research. 435(2). 113947–113947. 23 indexed citations
3.
Gao, Jun, Yuan Fang, Jiafeng Chen, et al.. (2023). Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy. Oncogene. 42(33). 2507–2520. 28 indexed citations
4.
Huang, Run, Guiqi Zhu, Xiutao Fu, et al.. (2022). Comprehensive analysis of complement-associated molecular features in hepatocellular carcinoma. Acta Biochimica et Biophysica Sinica. 54(11). 1694–1707. 1 indexed citations
5.
Zhu, Guiqi, Weiren Liu, Zheng Tang, et al.. (2021). Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. Molecular Oncology. 16(2). 549–561. 31 indexed citations
6.
Zhou, Yufu, Shushu Song, Meng‐Xin Tian, et al.. (2021). Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis. Journal for ImmunoTherapy of Cancer. 9(8). e003031–e003031. 45 indexed citations
7.
Qu, Wei‐Feng, Pei‐Yun Zhou, Wei‐Ren Liu, et al.. (2020). Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection. Annals of Translational Medicine. 8(7). 487–487. 28 indexed citations
8.
Liu, Wei‐Ren, Meng‐Xin Tian, Zheng Tang, et al.. (2020). Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. British Journal of Cancer. 123(1). 92–100. 11 indexed citations
9.
10.
Tian, Meng‐Xin, Weiren Liu, Chenyang Tao, et al.. (2020). Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: ISICC‐applied prediction model. Cancer Science. 111(4). 1084–1092. 16 indexed citations
11.
Tian, Meng‐Xin, Wei‐Ren Liu, Wei Deng, et al.. (2019). <p>Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma</p>. Cancer Management and Research. Volume 11. 5187–5195. 14 indexed citations
12.
Tang, Zheng, Wei‐Ren Liu, Pei‐Yun Zhou, et al.. (2019). Prognostic Value and Predication Model of Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma. Journal of Cancer. 10(22). 5575–5584. 35 indexed citations
13.
Tian, Meng‐Xin, Yufu Zhou, Wei‐Feng Qu, et al.. (2019). Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy. Cancer Immunology Immunotherapy. 68(8). 1369–1378. 12 indexed citations
14.
Tian, Meng‐Xin, Wei‐Ren Liu, Han Wang, et al.. (2019). Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. BMC Medicine. 17(1). 106–106. 28 indexed citations
15.
Tao, Chenyang, Wei‐Ren Liu, Lei Jin, et al.. (2018). Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. Journal of Cancer. 9(6). 1106–1112. 17 indexed citations
16.
Tian, Meng‐Xin, Wenjun He, Wei‐Ren Liu, et al.. (2018). A Novel Risk prediction Model for Patients with Combined Hepatocellular-Cholangiocarcinoma. Journal of Cancer. 9(6). 1025–1032. 15 indexed citations
17.
18.
Jiang, Xi‐Fei, Yang Dai, Peng Xia, et al.. (2017). SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models. Acta Pharmacologica Sinica. 39(2). 243–250. 16 indexed citations
19.
Liu, Wei‐Ren, Lei Jin, Meng‐Xin Tian, et al.. (2015). Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology. 40(2). 169–178. 34 indexed citations
20.
Tian, Meng‐Xin, Weiren Liu, Lei Jin, et al.. (2015). LOXL4 is downregulated in hepatocellular carcinoma with a favorable prognosis.. PubMed. 8(4). 3892–900. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chao‐Nan Qian Breakdown of academic impact, for papers by Norifumi Hattori Breakdown of academic impact, for papers by Thomas Armstrong Breakdown of academic impact, for papers by Laura July Breakdown of academic impact, for papers by Chunyan Luan Breakdown of academic impact, for papers by Junyan Xu Breakdown of academic impact, for papers by Bettina Schwarz Breakdown of academic impact, for papers by Augusto J. Bastidas Breakdown of academic impact, for papers by Jan Sun
Rankless by CCL
2026